Skip to main content

Advertisement

Table 3 1,3 and 5 year-survival rate of gastric cancer patients according to clinicopathological features and miRNA 106b~25

From: Multivariate analysis of clinicopathological and prognostic significance of miRNA 106b~25 cluster in gastric cancer

Clinicopathological featuresTotalOS
1-YSR3-YSR5-YSRx2P
Age
 < 552095.042.90.002.9510.086
 ≥ 554092.552.527.5  
Sex
 Male5394.350.321.31.9450.163
 Female785.742.90.00  
Tumor location
 Proximal1693.856.318.83.2710.105
 Middle1291.733.30.00  
 Distal3290.652.37.9  
Tumor size (cm)
 < 52696.273.138.518.0010.000
 ≥5 3491.231.03.1  
Bormann type
 I + II1995.252.423.80.7720.380
 III + IV4192.347.90.160  
T stage
 T1, T21693.875.043.85.9140.015
 T3, T44490.940.19.4  
N stage
 N01994.789.547.419.4600.000
 N1–N34190.230.55.1  
TNM stage
 I, II2495.883.341.724.4500.000
 III, IV3688.932.22.9  
Histological grade (-differentiated)
 Well1794.152.923.50.4450.505
 Poor4390.748.116.8  
Plasma miRNA 106ba
 Low3096.769.238.117.2190.000
 High3086.730.00.00  
Plasma miRNA 93a
 Low3096.766.733.38.4010.004
 High3090.031.73.5  
Plasma miRNA 25a
 Low3096.759.131.35.3580.029
 High3090.040.06.7  
Tumor miRNA 106ba
 Low3096.366.733.312.5330.000
 High3087.935.36.4  
Tumor miRNA 93a
 Low3096.366.733.79.3180.002
 High3087.935.36.4  
Tumor miRNA 25a
 Low3096.772.731.210.0470.002
 High3086.726.76.7  
  1. YSR year survival rate
  2. aMedian was set as cut-off value; low was ≤ median; high was > median